Rotavirus Infections - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：59頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Rotavirus Infections - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Rotavirus Infections - Pipeline Review, H1 2014’, provides an overview of the Rotavirus Infections’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Rotavirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rotavirus Infections and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Rotavirus Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Rotavirus Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Rotavirus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Rotavirus Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Rotavirus Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Rotavirus Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Rotavirus Infections - Pipeline Review, H1 2014’, provides an overview of the Rotavirus Infections’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Rotavirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rotavirus Infections and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Rotavirus Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Rotavirus Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Rotavirus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Rotavirus Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Rotavirus Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Rotavirus Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Rotavirus Infections Overview 7
Therapeutics Development 8
Pipeline Products for Rotavirus Infections - Overview 8
Pipeline Products for Rotavirus Infections - Comparative Analysis 9
Rotavirus Infections - Therapeutics under Development by Companies 10
Rotavirus Infections - Therapeutics under Investigation by Universities/Institutes 12
Rotavirus Infections - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Rotavirus Infections - Products under Development by Companies 16
Rotavirus Infections - Products under Investigation by Universities/Institutes 17
Rotavirus Infections - Companies Involved in Therapeutics Development 18
Takeda Pharmaceutical Company Limited 18
Biological E. Limited 19
Medicago Inc. 20
Immuron Limited 21
Bharat Biotech International Limited 22
Shantha Biotechnics Limited 23
Sinovac Biotech Ltd. 24
Seek 25
Serum Institute of India Limited 26
Beijing Minhai Biotechnology Co., Ltd 27
Rotavirus Infections - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 32
Assessment by Molecule Type 33
Drug Profiles 35
ORV-116E - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
IMM-272 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Rotavirus Vaccine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Rotavirus Vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Rotavirus Vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Rotavirus Vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
T-Cell Vaccine For Rotavirus - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Rotavirus VLP Vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Flagellin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Rotavirus Vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Anti-HRV-3IgY - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
5-Valent Rotavirus Vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Rotavirus Vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Monoclonal Antibody to Inhibit Nucleocapsid Protein for Rotavirus Infection - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Rotavirus Infections - Recent Pipeline Updates 50
Rotavirus Infections - Dormant Projects 51
Rotavirus Infections - Product Development Milestones 52
Featured News & Press Releases 52
Jun 20, 2013: Medicago Successfully Produces Plant-based Rotavirus VLP Vaccine Candidate 52
May 14, 2013: Bharat Biotech's Rotavirus Vaccine Demonstrates Strong Efficacy In Phase III Clinical Trial 52
Nov 10, 2012: GSK's Rotarix Vaccine To Help Protect Babies Against Rotavirus 54
Apr 26, 2012: GSK’s Rotarix To Be Introduced In Ghana 55
Nov 21, 2011: GSK And Daiichi Sankyo To Launch Rotarix Oral Liquid Formulation To Prevent Rotavirus Gastroenteritis In Japan 55
Jun 06, 2011: Bharat Biotech Announces Price Of Potential Vaccine Against Rotavirus Diarrhoea 56
May 19, 2010: Health Sciences Authority Provides Update On Review Of Presence Of Porcine Circovirus In GSK's Rotarix 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59
List of Tables
Number of Products under Development for Rotavirus Infections, H1 2014 8
Number of Products under Development for Rotavirus Infections - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Products under Investigation by Universities/Institutes, H1 2014 17
Rotavirus Infections - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 18
Rotavirus Infections - Pipeline by Biological E. Limited, H1 2014 19
Rotavirus Infections - Pipeline by Medicago Inc., H1 2014 20
Rotavirus Infections - Pipeline by Immuron Limited, H1 2014 21
Rotavirus Infections - Pipeline by Bharat Biotech International Limited, H1 2014 22
Rotavirus Infections - Pipeline by Shantha Biotechnics Limited, H1 2014 23
Rotavirus Infections - Pipeline by Sinovac Biotech Ltd., H1 2014 24
Rotavirus Infections - Pipeline by Seek, H1 2014 25
Rotavirus Infections - Pipeline by Serum Institute of India Limited, H1 2014 26
Rotavirus Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2014 27
Assessment by Monotherapy Products, H1 2014 28
Number of Products by Stage and Target, H1 2014 30
Number of Products by Stage and Mechanism of Action, H1 2014 31
Number of Products by Stage and Route of Administration, H1 2014 32
Number of Products by Stage and Molecule Type, H1 2014 34
Rotavirus Infections Therapeutics - Recent Pipeline Updates, H1 2014 50
Rotavirus Infections - Dormant Projects, H1 2014 51
List of Figures
Number of Products under Development for Rotavirus Infections, H1 2014 8
Number of Products under Development for Rotavirus Infections - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Products, H1 2014 15
Assessment by Monotherapy Products, H1 2014 28
Number of Products by Top 10 Target, H1 2014 29
Number of Products by Stage and Top 10 Target, H1 2014 30
Number of Products by Stage and Top 10 Route of Administration, H1 2014 32
Number of Products by Top 10 Molecule Type, H1 2014 33
Number of Products by Stage and Top 10 Molecule Type, H1 2014 34
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Rotavirus Infections Overview 7
Therapeutics Development 8
Pipeline Products for Rotavirus Infections - Overview 8
Pipeline Products for Rotavirus Infections - Comparative Analysis 9
Rotavirus Infections - Therapeutics under Development by Companies 10
Rotavirus Infections - Therapeutics under Investigation by Universities/Institutes 12
Rotavirus Infections - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Rotavirus Infections - Products under Development by Companies 16
Rotavirus Infections - Products under Investigation by Universities/Institutes 17
Rotavirus Infections - Companies Involved in Therapeutics Development 18
Takeda Pharmaceutical Company Limited 18
Biological E. Limited 19
Medicago Inc. 20
Immuron Limited 21
Bharat Biotech International Limited 22
Shantha Biotechnics Limited 23
Sinovac Biotech Ltd. 24
Seek 25
Serum Institute of India Limited 26
Beijing Minhai Biotechnology Co., Ltd 27
Rotavirus Infections - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 32
Assessment by Molecule Type 33
Drug Profiles 35
ORV-116E - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
IMM-272 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Rotavirus Vaccine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Rotavirus Vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Rotavirus Vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Rotavirus Vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
T-Cell Vaccine For Rotavirus - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Rotavirus VLP Vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Flagellin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Rotavirus Vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Anti-HRV-3IgY - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
5-Valent Rotavirus Vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Rotavirus Vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Monoclonal Antibody to Inhibit Nucleocapsid Protein for Rotavirus Infection - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Rotavirus Infections - Recent Pipeline Updates 50
Rotavirus Infections - Dormant Projects 51
Rotavirus Infections - Product Development Milestones 52
Featured News & Press Releases 52
Jun 20, 2013: Medicago Successfully Produces Plant-based Rotavirus VLP Vaccine Candidate 52
May 14, 2013: Bharat Biotech's Rotavirus Vaccine Demonstrates Strong Efficacy In Phase III Clinical Trial 52
Nov 10, 2012: GSK's Rotarix Vaccine To Help Protect Babies Against Rotavirus 54
Apr 26, 2012: GSK’s Rotarix To Be Introduced In Ghana 55
Nov 21, 2011: GSK And Daiichi Sankyo To Launch Rotarix Oral Liquid Formulation To Prevent Rotavirus Gastroenteritis In Japan 55
Jun 06, 2011: Bharat Biotech Announces Price Of Potential Vaccine Against Rotavirus Diarrhoea 56
May 19, 2010: Health Sciences Authority Provides Update On Review Of Presence Of Porcine Circovirus In GSK's Rotarix 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59
List of Tables
Number of Products under Development for Rotavirus Infections, H1 2014 8
Number of Products under Development for Rotavirus Infections - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Products under Investigation by Universities/Institutes, H1 2014 17
Rotavirus Infections - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 18
Rotavirus Infections - Pipeline by Biological E. Limited, H1 2014 19
Rotavirus Infections - Pipeline by Medicago Inc., H1 2014 20
Rotavirus Infections - Pipeline by Immuron Limited, H1 2014 21
Rotavirus Infections - Pipeline by Bharat Biotech International Limited, H1 2014 22
Rotavirus Infections - Pipeline by Shantha Biotechnics Limited, H1 2014 23
Rotavirus Infections - Pipeline by Sinovac Biotech Ltd., H1 2014 24
Rotavirus Infections - Pipeline by Seek, H1 2014 25
Rotavirus Infections - Pipeline by Serum Institute of India Limited, H1 2014 26
Rotavirus Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2014 27
Assessment by Monotherapy Products, H1 2014 28
Number of Products by Stage and Target, H1 2014 30
Number of Products by Stage and Mechanism of Action, H1 2014 31
Number of Products by Stage and Route of Administration, H1 2014 32
Number of Products by Stage and Molecule Type, H1 2014 34
Rotavirus Infections Therapeutics - Recent Pipeline Updates, H1 2014 50
Rotavirus Infections - Dormant Projects, H1 2014 51
List of Figures
Number of Products under Development for Rotavirus Infections, H1 2014 8
Number of Products under Development for Rotavirus Infections - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Products, H1 2014 15
Assessment by Monotherapy Products, H1 2014 28
Number of Products by Top 10 Target, H1 2014 29
Number of Products by Stage and Top 10 Target, H1 2014 30
Number of Products by Stage and Top 10 Route of Administration, H1 2014 32
Number of Products by Top 10 Molecule Type, H1 2014 33
Number of Products by Stage and Top 10 Molecule Type, H1 2014 34
